Get the Stockscreener App
2.07
2.08%
0.15
Curis Inc stock is traded at $2.07, with a volume of 58,819.
It is up +2.08% in the last 24 hours and up +39.16% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$1.92
Open:
$1.94
24h Volume:
58,819
Relative Volume:
0.78
Market Cap:
$20.82M
Revenue:
$10.16M
Net Income/Loss:
$-47.57M
P/E Ratio:
-0.2512
EPS:
-8.24
Net Cash Flow:
$-42.73M
1W Performance:
-0.50%
1M Performance:
+39.16%
6M Performance:
-50.62%
1Y Performance:
-81.61%
1-Day Range:
$1.93
$2.01
1-Week Range:
$1.84
$2.19
52-Week Range:
$1.02
$11.49
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.99 | 20.92M | 10.16M | -47.57M | -42.73M | -8.24 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Curis Approves Key Amendments at Annual Meeting - TipRanks
What is HC Wainwright’s Estimate for Curis Q2 Earnings? - Defense World
Curis (NASDAQ:CRIS) Receives Buy Rating from HC Wainwright - Defense World
Curis (CRIS) Sees Positive Rating Action from HC Wainwright & Co - GuruFocus
Curis assumed with a Buy at H.C. Wainwright - TipRanks
H.C. Wainwright sets $17 target for Curis stock with Buy rating - Investing.com Nigeria
Curis (CRIS) Gains Buy Rating with Promising Cancer Therapy Deve - GuruFocus
Curis (CRIS) Gains Buy Rating with Promising Cancer Therapy Developments | CRIS Stock News - GuruFocus
Curis Provides Third Quarter 2023 Business Update - Seeking Alpha
Curis (NASDAQ:CRIS) Now Covered by Analysts at StockNews.com - Defense World
FY2025 EPS Estimates for Curis Reduced by Cantor Fitzgerald - Defense World
Curis highlights progress in lymphoma and AML trials with expanded patient enrollment - MSN
Curis, Inc. (NASDAQ:CRIS) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Ardent Health Partners, Inc. (ARDT) and Agilon Health (AGL) - The Globe and Mail
Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com - Defense World
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | CRIS Stock News - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic Developments - Yahoo Finance
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Imp - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic Developments By GuruFocus - Investing.com Canada
Curis Inc. Reports Q1 2025 Progress and Financials - TipRanks
Curis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Curis Inc. Earnings Call: Clinical Advances Amid Cash Concerns - TipRanks
Curis: Q1 Earnings Snapshot - MySA
Curis Q1 2025 Earnings Call Transcript - MarketBeat
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GuruFocus
Curis, Inc. (CRIS) Advances Emavusertib Studies with Positive Da - GuruFocus
Curis (CRIS) Strengthens Leadership with New Chief Medical Officer | CRIS Stock News - GuruFocus
Curis appoints Ahmed Hamdy as Chief Medical Officer - TipRanks
Curis reports Q1 EPS ($1.25), consensus ($1.26) - TipRanks
Earnings call transcript: Curis Inc. Q1 2025 sees stock surge despite losses - Investing.com India
Curis Provides First Quarter 2025 Business Update - StreetInsider
Curis (CRIS) Expands Leadership and Advances Clinical Studies | - GuruFocus
Curis Provides First Quarter 2025 Business Update | CRIS Stock N - GuruFocus
Curis Inc (CRIS) Q1 2025 Earnings: EPS of -$1.25 Misses Estimates, Revenue of $2.4M Falls Short - GuruFocus
Curis (CRIS) Expands Leadership and Advances Clinical Studies | CRIS Stock News - GuruFocus
Curis Provides First Quarter 2025 Business Update | CRIS Stock News - GuruFocus
CURIS INC SEC 10-Q Report - TradingView
Curis Inc Q1 Loss Decreases, Beats Estimates - Nasdaq
Curis Inc (CRIS) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Curis Provides Third Quarter 2024 Business Update - Seeking Alpha
Geode Capital Management LLC Raises Position in Curis, Inc. (NASDAQ:CRIS) - Defense World
Curis FY2025 EPS Estimate Increased by Cantor Fitzgerald - Defense World
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
5.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):